Nanotargeting of Drug(s) for Delaying Dementia: Relevance of Covid-19 Impact on Dementia

American Journal of Alzheimer's Disease &Other Dementiasr, Volume 35, Issue , January-December 2020. By incorporating appropriate drug(s) into lipid (biobased) nanocarriers, one obtains a combination therapeutic for dementia treatment that targets certain cell-surface scavenger receptors (mainly class B type I, or “SR-BI”) and thereby crosses the blood-brain barrier. The cardiovascular risk factors for dementia trigger widespread inflammation -- which lead to neurodegeneration, gradual cogn...
More

The Effects of COVID-19 Home Confinement in Dementia Care: Physical and Cognitive Decline, Severe Neuropsychiatric Symptoms and Increased Caregiving Burden

American Journal of Alzheimer's Disease &Other Dementiasr, Volume 35, Issue , January-December 2020. Purpose:This study aims to analyze home confinement impact on individuals with neurocognitive disorders (NCD) through informal caregiver’s perspective and examine how it has affected caregiving burden.Methods:Thirty-six caregivers (64.94 ± 13.54 years, 41.7% female) of individuals with NCD (74.28 ± 6.76 years, 66.7% female) selected from the Body & Brain exercise program were interviewed...
More

A Study on PHF-Tau Network Effected by Apolipoprotein E4

American Journal of Alzheimer's Disease &Other Dementiasr, Volume 35, Issue , January-December 2020. Apolipoprotein E 4 Allele (APOE 4) is an important factors in Mild cognitive impairment (MCI) and Alzheimer’s disease(AD). It plays a primary role in abnormal modification of aggregated Tau protein-paired helical filaments Tau (PHF-Tau). In this study, 143 subjects with PHF-Tau PET were divided into 2 groups (APOE 4 carriers and noncarriers). The measurements of the PHF-Tau network propertie...
More